Guardant Health Hits 52-Week High on $210M Volume Ranking 463rd Amid Institutional BuySell Splits

Guardant Health (GH) surged 3.06% on August 14, 2025, with a trading volume of $210 million, ranking 463rd in market activity. The stock closed at $59.25, hitting a 52-week high. Institutional activity included XTX Topco Ltd reducing its stake by 84.3% in Q1, while NewEdge Advisors and TD Waterhouse increased holdings by 13.5% and 126.2%, respectively. Analysts from TD Securities, Evercore ISI, and Canaccord Genuity upgraded their ratings, with price targets raised to $60–$65. Insider sales by directors Ian T. Clark and Meghan Joyce totaled $480,364.40, representing 40.38% and 23.03% reductions in their positions. The stock’s 50-day moving average stands at $48.55, with a 12-month high of $55.69.

Institutional ownership remains strong, with 92.60% of shares held by hedge funds and other investors. Recent upgrades from six analysts highlight growing confidence, though insider selling and reduced stakes by XTX Topco signal mixed sentiment. The company’s revenue rose 31% year-over-year in Q2, outpacing expectations, but earnings remained negative at -$0.44 per share. Analysts project a -2.9 EPS for the fiscal year, underscoring ongoing profitability challenges despite market optimism.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to present yielded a total profit of $10,720 as of the latest data. This reflects moderate returns amid market fluctuations, aligning with GH’s recent volatility and sector dynamics.